Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified HD95 in young adults with classical Hodgkin lymphoma
2007-003080-45Phase 2Completed
- Sponsor
- University College London
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, etoposide, vincristine, prednisolone, cyclophosphamide and 2 more in classical Hodgkin lymphoma (cHL), sponsored by University College London. Primary endpoints: Neurotoxicity / treatment toxicity and Efficacy reproduction of pediatric HD95 outcomes. Started Sep 2007; status: completed.
02
Drugs
doxorubicinetoposidevincristineprednisolonecyclophosphamide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2007-003080-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003080-45.